Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony

Parasitology

Volumn 138, Issue 2, 2011, Pages 183-193

  Adaui, V ^a,b   Schnorbusch, K ^b,c   Zimic, M ^d   Gutirrez, A ^d   Decuypere, S ^b   Vanaerschot, M ^b,c   De Doncker, S ^b   Maes, I ^b   Llanos Cuentas, A ^a   Chappuis, F ^e   Arvalo, J ^a,d   Dujardin, J C ^b,c  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

antimony resistance; clinical isolates; gene expression profiling; Leishmania (Viannia) braziliensis; promastigotes

Indexed keywords

ANTIMONY; MOLECULAR MARKER; ORNITHINE DECARBOXYLASE; PENTAVALENT ANTIMONY; RNA; TRYPANOTHIONE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HOUSEKEEPING GENE; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; NONHUMAN; OXIDATIVE STRESS; PARASITE ISOLATION; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

ANIMALS; ANTIMONY; CELL CULTURE TECHNIQUES; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETIC PLEIOTROPY; GENETIC VARIATION; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; NADH, NADPH OXIDOREDUCTASES; ORNITHINE DECARBOXYLASE; PARASITIC SENSITIVITY TESTS;

LEISHMANIA BRAZILIENSIS;

EID: 79952986204     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182010001095     Document Type: Article

References (34)

1. Ashutosh, Sundar, S. and Goyal, N. (2007). Molecular mechanisms of antimony resistance in Leishmania. Journal of Medical Microbiology 56, 143-153.
2. Arevalo, J., Ramirez, L., Adaui, V., Zimic, M., Tulliano, G., Miranda-Verastegui, C., Lazo, M., Loayza-Muro, R., De Doncker, S., Maurer, A., Chappuis, F., Dujardin, J. C. and Llanos-Cuentas, A. (2007). The influence of Leishmania (Viannia) species on the response to antimonial treatment of patients with American Tegumentary Leishmaniasis. Journal of Infectious Diseases 195, 1846-1851. (Pubitemid 46870258)
3. Da Silva, R. and Sacks, D. L. (1987). Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infection and Immunity 55, 2802-2806. (Pubitemid 17154527)
4. Decuypere, S. (2007). Antimonial treatment failure in anthroponotic visceral leishmaniasis: towards improved tools and strategies for epidemiological surveillance and disease control. Ph.D. thesis. University of Antwerp, Antwerp, Belgium.
5. Decuypere, S., Rijal, S., Yardley, V., De Doncker, S., Laurent, T., Khanal, B., Chappuis, F. and Dujardin, J. C. (2005). Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrobial Agents and Chemotherapy 49, 4616-4621. (Pubitemid 41552591)
6. Decuypere, S., Vanaerschot, M., Rijal, S., Yardley, V., Maes, L., De Doncker, S., Chappuis, F. and Dujardin, J. C. (2008). Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation. Parasitology 135, 183-194. (Pubitemid 351156582)
7. Dias, F. C., Ruiz, J. C., Lopes, W. C., Squina, F. M., Renzi, A., Cruz, A. K. and Tosi, L. R. (2007). Organization of H locus conserved repeats in Leishmania (Viannia) braziliensis correlates with lack of gene amplification and drug resistance. Parasitology Research 101, 667-676. (Pubitemid 47101426)
8. Dujardin, J. C. (2009). Structure, dynamics and function of Leishmania genome: resolving the puzzle of infection, genetics and evolution? Infection, Genetics and Evolution 9, 290-297.
9. Gamboa, D., Van Eys, G., Victoir, K., Torres, K., Adaui, V., Arevalo, J. and Dujardin, J. C. (2007). Putative markers of infective life stages in Leishmania (Viannia) braziliensis. Parasitology 134, 1689-1698. (Pubitemid 47530766)
10. Garcia, A. L., Kindt, A., Quispe-Tintaya, K.W., Bermudez, H., Llanos, A., Arevalo, J., Bañuls, A. L., De Doncker, S., Le Ray, D. and Dujardin, J. C. (2005). American tegumentary leishmaniasis: Antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infection, Genetics and Evolution 5, 109-116. (Pubitemid 40090229)
11. Hadighi, R., Mohebali, M., Boucher, P., Hajjaran, H., Khamesipour, A. and Ouellette, M. (2006). Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Medicine 3, e162.
12. Haimeur, A., Guimond, C., Pilote, S., Mukhopadhyay, R., Rosen, B. P., Poulin, R. and Ouellette, M. (1999). Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Molecular Microbiology 34, 726-735.
13. Hellemans, J., Mortier, G., De Paepe, A., Speleman, F. and Vandesompele, J. (2007). qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biology 8, R19.
14. Laurent, T., Rijal, S., Yardley, V., Croft, S., De Doncker, S., Decuypere, S., Khanal, B., Singh, R., Schönian, G., Kuhls, K., Chappuis, F. and Dujardin, J. C. (2007). Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infection, Genetics and Evolution 7, 206-212. (Pubitemid 46172947)
15. Lira, R., Sundar, S., Makharia, A., Kenney, R., Gam, A., Saraiva, E. and Sacks, D. (1999). Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. The Journal of Infectious Diseases 180, 564-567. (Pubitemid 30256350)
16. Mandal, G., Wyllie, S., Singh, N., Sundar, S., Fairlamb, A. H. and Chatterjee, M. (2007). Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. Parasitology 134, 1679-1687. (Pubitemid 47530771)
17. McCarthy, D. J. and Smyth, G. K. (2009). Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 25, 765-771.
18. Mittal, M. K., Rai, S., Ashutosh, Ravinder, Gupta, S., Sundar, S. and Goyal, N. (2007). Characterization of natural antimony resistance in Leishmania donovani isolates. American Journal of Tropical Medicine and Hygiene 76, 681-688. (Pubitemid 351627707)
19. Mukherjee, A., Padmanabhan, P. K., Singh, S., Roy, G., Girard, I., Chatterjee, M., Ouellette, M. and Madhubala, R. (2007). Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. Journal of Antimicrobial Chemotherapy 59, 204-211. (Pubitemid 47072058)
20. Murray, H.W., Berman, J. D., Davies, C. R. and Saravia, N. G. (2005). Advances in leishmaniasis. Lancet 366, 1561-1577. (Pubitemid 41540115)
21. Neal, R. A. and Croft, S. L. (1984). An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. Journal of Antimicrobial Chemotherapy 14, 463-475. (Pubitemid 15079025)
22. Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., Kerhornou, A., Ivens, A. and others. (2007). Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nature Genetics 39, 839-847. (Pubitemid 47014491)
23. Rijal, S., Yardley, V., Chappuis, F., Decuypere, S., Khanal, B., Singh, R., Boelaert, M., De Doncker, S., Croft, S. and Dujardin, J. C. (2007). Antimonial treatment of visceral leishmaniasis: Are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes and Infection 9, 529-535. (Pubitemid 46442794)
24. Rojas, R., Valderrama, L., Valderrama, M., Varona, M. X., Ouellette, M. and Saravia, N. G. (2006). Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. The Journal of Infectious Diseases 193, 1375-1383. (Pubitemid 43673385)
25. Rozen, S. and Skaletsky, H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods in Molecular Biology 132, 365-386.
26. Sacks, D. L. (1989). Metacyclogenesis in Leishmania promastigotes. Experimental Parasitology 69, 100-103. (Pubitemid 19187905)
27. Saxena, A., Worthey, E. A., Yan, S., Leland, A., Stuart, K. D. and Myler, P. J. (2003). Evaluation of differential gene expression in Leishmania major Friedlin procyclics and metacyclics using DNA microarray analysis. Molecular and Biochemical Parasitology 129, 103-114. (Pubitemid 36703227)
28. Smith, D. F., Peacock, C. S. and Cruz, A. K. (2007). Comparative genomics: From genotype to disease phenotype in the leishmaniases. International Journal for Parasitology 37, 1173-1186. (Pubitemid 47088471)
29. Torres, D. C., Adaui, V., Alves, M. R., Romero, G. A. S., Arevalo, J., Cupolillo, E. and Dujardin, J. C. (2010). Gene expression profiling in Leishmania braziliensis and Leishmania guyanensis clinical isolates with different treatment outcome from Brazil. Infection Genetics and Evolution May 15 (Epub ahead of print).
30. Uliana, S. R., Goyal, N., Freymüller, E. and Smith, D. F. (1999). Leishmania: overexpression and comparative structural analysis of the stage-regulated meta 1 gene. Experimental Parasitology 92, 183-191. (Pubitemid 29370061)
31. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A. and Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3, research0034.I-0034.II.
32. Vermeersch, M., da Luz, R. I., Toté, K., Timmermans, J. P., Cos, P. and Maes, L. (2009). In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrobial Agents and Chemotherapy 53, 3855-3859.
33. Yardley, V., Ortuño, N., Llanos-Cuentas, A., Chappuis, F., De Doncker, S., Ramirez, L., Croft, S., Arevalo, J., Adaui, V., Bermudez, H., Decuypere, S. and Dujardin, J. C. (2006). American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility? The Journal of Infectious Diseases 194, 1168-1175. (Pubitemid 44547658)
34. Youden, W. J. (1950). Index for rating diagnostic tests. Cancer 3, 32-35.